MELBOURNE, Australia (BUSINESS WIRE) Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering
Propanc Biopharma, Inc. ("Propanc" or the "Company"), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, today announced that PRP enhances the sensitivity of resistant.
Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) was the recipient of a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 35,000 shares, an increase of 18.2% from the September 30th total of 29,600 shares. Based on an average daily trading volume, of 802,500 […]
Propanc Biopharma, Inc. (OTCMKTS:PPCB – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 35,800 shares, an increase of 21.8% from the June 30th total of 29,400 shares. Based on an average trading volume of 1,291,300 shares, […]